1. Introduction

Cost-Effectiveness Regulation of Biotech Drugs refers to the legal and institutional framework through which governments evaluate whether the clinical benefits, therapeutic outcomes and public-health value of biotechnology-based medicines justify their financial costs.

Biotech drugs include biologics, monoclonal antibodies, recombinant proteins, vaccines, gene therapies, cell therapies, biosimilars and other advanced biological medicinal products.

Unlike conventional chemical medicines, biotech drugs frequently involve:

Complex biological manufacturing processes.

Expensive research and clinical development.

Sophisticated storage and distribution requirements.

High prices arising from patents, exclusivity and limited competition.

Uncertain long-term clinical outcomes.

Significant public expenditure through government-funded healthcare systems.

Consequently, regulators must balance two important objectives:

Patient access: Ensuring that patients can obtain innovative and life-saving biological medicines.

Economic sustainability: Preventing unjustified prices and ensuring that limited healthcare resources are allocated efficiently.

Cost-effectiveness regulation therefore seeks to establish whether a biotech drug produces sufficient additional health benefits in comparison with its additional financial cost.

It is important to distinguish cost-effectiveness regulation from drug approval. Regulatory approval primarily evaluates quality, safety and efficacy, whereas health technology assessment (HTA) evaluates the medicine's comparative clinical and economic value.

2. Meaning and Legal Foundations

Cost-effectiveness analysis (CEA) compares the additional costs of a new medicine with the additional health benefits it produces compared with an existing treatment.

The central measurement is the incremental cost-effectiveness ratio (ICER):

\[ ICER=\frac{C_1-C_0}{E_1-E_0} \]

Where:

\(C_1\) = Cost of the new biotech drug.

\(C_0\) = Cost of the existing treatment.

\(E_1\) = Health outcome achieved through the new drug.

\(E_0\) = Health outcome achieved through the existing treatment.

Health outcomes may be measured through survival, reduction in disease progression, quality-adjusted life years (QALYs), disability-adjusted life years (DALYs), or other clinically meaningful outcomes.

Example:

Suppose a new monoclonal antibody costs ₹10 lakh more than conventional treatment and produces an additional two QALYs.

\[ ICER=\frac{₹10,00,000}{2}=₹5,00,000 \]

The additional cost is ₹5 lakh per additional QALY.

Whether this is acceptable depends on the applicable healthcare system's evaluation criteria, budget constraints, disease severity and competing healthcare priorities. There is no universal legal threshold applicable to every country.

3. Objectives of Cost-Effectiveness Regulation

The principal objectives include:

A. Affordable access: Ensuring that expensive biological medicines do not become inaccessible to economically disadvantaged patients.

B. Rational allocation of healthcare resources: Directing limited public healthcare budgets towards interventions that generate meaningful health benefits.

C. Prevention of excessive pricing: Examining whether the price of a biotech drug is justified by its incremental therapeutic value.

D. Encouragement of innovation: Protecting legitimate incentives for biotechnology research while preventing unjustified monopolistic pricing.

E. Biosimilar competition: Encouraging the entry of comparable biological medicines to reduce treatment expenditure.

F. Transparency and accountability: Requiring manufacturers and public authorities to justify economic decisions through credible clinical and financial evidence.

4. Principal Regulatory Mechanisms

4.1 Health Technology Assessment

HTA is one of the most important instruments of cost-effectiveness regulation.

It examines:

Clinical effectiveness.

Comparative safety.

Treatment costs.

Cost per QALY.

Long-term healthcare expenditure.

Budget impact.

Patient-reported outcomes.

Uncertainty in clinical evidence.

For example, a new cancer immunotherapy may demonstrate superior survival outcomes but cost several times more than existing treatment. HTA determines whether the additional clinical benefit justifies the additional expenditure.

HTA recommendations may influence reimbursement, insurance coverage, procurement and public funding.

4.2 Cost-Effectiveness Thresholds

Some healthcare systems use explicit or implicit cost-effectiveness thresholds.

A medicine may be considered economically attractive when its ICER falls below the applicable threshold.

However, thresholds are not absolute legal entitlements. Decision-makers may also consider:

Rare diseases.

Serious or life-threatening conditions.

Unmet medical needs.

Paediatric treatment.

Lack of alternative therapies.

Severity and duration of illness.

A rigid threshold may disadvantage patients with rare diseases because developing treatments for small patient populations is frequently expensive.

4.3 Reference Pricing

Reference pricing involves comparing the prices of medicines with comparable treatments or prices in other jurisdictions.

It can involve:

Internal reference pricing.

External international reference pricing.

Therapeutic reference pricing.

Reference pricing for biosimilars.

Its purpose is to prevent excessive price differences and strengthen negotiating power.

4.4 Outcomes-Based Pricing

Under outcomes-based arrangements, payment is connected with the actual therapeutic performance of a medicine.

For example, a manufacturer supplying a gene therapy may agree to financial rebates if the treatment fails to achieve specified clinical outcomes.

Such agreements require reliable patient monitoring, clear contractual standards and protection of confidential medical information.

4.5 Budget Impact Assessment

Cost-effectiveness and affordability are not identical.

A medicine may be cost-effective for an individual patient but financially unaffordable when prescribed to millions of patients.

Budget impact assessment estimates the total financial consequences of introducing the medicine into a healthcare system.

4.6 Biosimilar Competition

Biosimilars are biological medicines demonstrated to be highly similar to an already authorised reference biological medicine, without clinically meaningful differences in relevant quality, safety and efficacy.

Their availability may reduce expenditure through:

Price competition.

Competitive public procurement.

Reduced dependence on a single manufacturer.

Expansion of treatment access.

However, biosimilar regulation must maintain stringent standards of manufacturing quality, comparability, pharmacovigilance and traceability.

5. Indian Legal and Regulatory Framework

India does not operate a single, comprehensive statutory system in which every biotech drug must pass a mandatory cost-per-QALY threshold before receiving marketing approval or reimbursement. Instead, several regulatory mechanisms collectively influence affordability, pricing, clinical evaluation and public access.

5.1 Drugs and Cosmetics Act, 1940

The Drugs and Cosmetics Act, 1940 provides the principal statutory framework for regulating the import, manufacture, distribution and sale of drugs in India.

Its relevance to biotech medicines includes:

Quality and safety requirements.

Manufacturing standards.

Regulatory supervision of biological products.

Compliance with applicable licensing requirements.

Prevention of substandard and unsafe medicines.

The Central Drugs Standard Control Organisation (CDSCO) and the Drugs Controller General of India (DCGI) administer important aspects of drug regulation.

The Act is principally concerned with the regulatory quality, safety and efficacy of medicines; it does not establish a general economic cost-effectiveness threshold for biotech drug approval.

5.2 Drugs (Prices Control) Order, 2013

The Drugs (Prices Control) Order, 2013 operates under Section 3 of the Essential Commodities Act, 1955.

It provides the statutory basis for government intervention in pharmaceutical prices.

Its important mechanisms include:

Fixation of ceiling prices for scheduled formulations.

Regulation of maximum retail prices.

Monitoring of non-scheduled formulations.

Prevention of excessive price increases.

Recovery of overcharged amounts.

Enforcement against manufacturers violating applicable price restrictions.

The National Pharmaceutical Pricing Authority (NPPA) administers important pricing functions under this framework.

nppa.gov.in+2

An important distinction is that price control under DPCO is not the same as a formal cost-effectiveness assessment. A biotech drug's inclusion in price regulation depends on the applicable statutory and scheduling framework, rather than simply its ICER.

5.3 National List of Essential Medicines

The National List of Essential Medicines (NLEM), 2022 provides an important basis for identifying medicines requiring priority attention in pricing policy.

Medicines included in Schedule I of DPCO are subject to the applicable ceiling-price mechanism.

The essential-medicines framework attempts to balance:

Therapeutic importance.

Public-health requirements.

Availability.

Affordability.

Pharmaceutical market conditions.

However, an innovative biologic does not automatically receive price regulation merely because it is medically important. Its legal treatment depends on the applicable inclusion and pricing provisions.

5.4 Health Technology Assessment in India

India has developed the Health Technology Assessment in India (HTAIn) initiative under the Department of Health Research.

HTAIn evaluates health interventions through clinical, economic and social considerations.

Its work can support decisions concerning:

Public healthcare expenditure.

Introduction of expensive biological medicines.

Government-funded treatment programmes.

Comparative treatment effectiveness.

Economic value of innovative therapies.

Healthcare resource allocation.

HTAIn is particularly important because it provides an institutional basis for evaluating whether the additional benefits of a new treatment justify its additional expenditure.

However, HTA recommendations should not be confused with statutory marketing approval or automatic compulsory price fixation.

5.5 Competition Act, 2002

The Competition Act, 2002 is relevant where pharmaceutical companies engage in conduct that harms competition.

Potential concerns include:

Abuse of dominant position.

Exclusionary licensing arrangements.

Anti-competitive agreements.

Restrictive distribution practices.

Conduct restricting biosimilar competition.

Section 4 is particularly relevant to abuse of dominance.

An exceptionally high price is not automatically unlawful merely because it is high. The legal inquiry must establish the relevant competition-law requirements, including dominance and abusive conduct where applicable.

5.6 Patents Act, 1970

The Patents Act, 1970 is significant because biotechnology innovation frequently depends on patent protection.

However, patent rights are subject to statutory limitations and public-interest safeguards.

Important provisions include:

Section 84 is particularly relevant where the reasonable requirements of the public are not satisfied, the patented invention is not available at a reasonably affordable price, or the invention is not worked in India, subject to statutory conditions.

This creates an important connection between intellectual-property protection and access to expensive biotechnology medicines.

6. Important Judicial Decisions and Case Laws

Indian and international courts have addressed several legal questions closely connected with cost-effectiveness regulation, including affordability, reimbursement, pharmaceutical monopolies, healthcare allocation and the limits of government pricing decisions.

It is important to recognise that some of the following decisions are foundational access-to-medicines cases rather than direct judicial determinations of ICER methodology.

6.1 Novartis AG v. Union of India (2013) 6 SCC 1

Major Indian precedent

Background:

Novartis sought patent protection in India for a modified form of the cancer medicine imatinib mesylate, marketed as Glivec.

The dispute concerned Section 3(d) of the Patents Act, 1970, which restricts patent protection for certain new forms of known substances unless the statutory requirement of enhanced efficacy is satisfied.

Legal issue:

Whether the claimed new form demonstrated the enhanced therapeutic efficacy required under Section 3(d).

Judgment:

The Supreme Court rejected Novartis's appeal and upheld the refusal of the patent application.

The Court interpreted enhanced efficacy in the context of medicines as requiring enhanced therapeutic efficacy, rather than merely improved physical or pharmaceutical characteristics.

Relevance to biotech cost-effectiveness regulation:

The judgment is important because it demonstrates the relationship between pharmaceutical patent protection and public access to medicines.

It helps explain why patent law must balance:

Pharmaceutical innovation.

Legitimate intellectual-property rights.

Generic competition.

Affordable access to treatment.

Legal principle: Patent protection cannot be extended merely through incremental modifications that fail to satisfy statutory patentability requirements.

The decision does not establish a cost-per-QALY test, but it is important to the broader legal framework governing affordability and pharmaceutical competition.

6.2 Bayer Corporation v. Union of India (2014) 6 SCC 570

Background:

The dispute concerned the compulsory licensing of Bayer's patented cancer medicine sorafenib tosylate, marketed as Nexavar.

Natco Pharma sought a compulsory licence under Section 84 of the Patents Act, 1970.

Legal issues:

Whether reasonable requirements of the public were satisfied.

Whether the medicine was available at a reasonably affordable price.

Whether the patented invention was worked in India.

Judicial significance:

The litigation upheld the importance of applying the statutory compulsory-licensing framework to pharmaceutical patents.

The underlying compulsory-licensing proceedings recognised that patent exclusivity cannot be considered independently of public access and affordability.

Relevance:

The decision is particularly important for expensive biotech drugs because it demonstrates how intellectual-property law can accommodate public-health considerations.

Where statutory requirements are satisfied, compulsory licensing may facilitate the entry of additional manufacturers and improve access to essential medicines.

6.3 Union of India v. Cynamide India Ltd. (1987) 2 SCC 720

Background:

The case concerned governmental price fixation under the pharmaceutical price-control framework.

Legal issue:

Whether price fixation by the government under the relevant statutory framework was legislative or quasi-judicial in character.

Judgment:

The Supreme Court recognised that statutory price fixation is essentially legislative in character.

Relevance to biotech drugs:

This decision provides an important foundation for understanding governmental authority to regulate pharmaceutical prices.

It supports the principle that economic and public-interest considerations may justify government intervention in drug pricing within the limits of the enabling legislation.

It is relevant to the legal design of pricing controls for costly biological medicines.

6.4 Rogers v. Swindon NHS Primary Care Trust [2006] EWCA Civ 392

Important biologic-treatment funding case

Background:

The claimant, a breast-cancer patient, sought NHS funding for Herceptin (trastuzumab), a monoclonal antibody used in treating certain forms of breast cancer.

The relevant Primary Care Trust had adopted a policy restricting funding, subject to exceptional circumstances.

Legal issue:

Whether the NHS authority's funding policy was rational and legally defensible.

Judgment:

The Court of Appeal held that the authority's policy was irrational because it did not provide a proper clinical basis for distinguishing between patients within the eligible treatment group.

The Court emphasised that once the authority had decided to fund treatment for some patients, it could not arbitrarily exclude similarly situated patients.

Relevance to cost-effectiveness regulation:

This judgment illustrates that healthcare funding decisions must comply with public-law requirements.

Authorities cannot rely on arbitrary classifications or inconsistent funding policies.

For expensive biologics, economic considerations must be considered through a rational, transparent and legally defensible framework.

Importantly, the Court did not establish that every patient is automatically entitled to any expensive biologic medicine.

6.5 R (Condliff) v. North Staffordshire Primary Care Trust [2011] EWCA Civ 910

Background:

The case concerned NHS funding criteria for bariatric surgery and the claimant's challenge to the application of those criteria.

Legal issue:

Whether the healthcare authority's eligibility and resource-allocation policy was unlawful.

Judgment:

The Court of Appeal considered the legitimacy of healthcare resource allocation and the lawfulness of the criteria applied by the public authority.

Relevance:

The case demonstrates that public healthcare institutions may adopt general eligibility and resource-allocation policies, provided that they comply with public-law standards.

The same principles are relevant to funding expensive gene therapies, biologics and other high-cost interventions.

The authorities must balance individual medical requirements with the wider needs of the patient population.

6.6 Paschim Banga Khet Mazdoor Samity v. State of West Bengal (1996) 4 SCC 37

Background:

The case concerned the failure of government hospitals to provide emergency medical treatment to an injured person.

Judgment:

The Supreme Court held that the State has a constitutional obligation to provide adequate medical facilities and that failure to provide timely treatment can violate Article 21 of the Constitution.

Relevance:

The judgment establishes an important constitutional foundation for healthcare access.

In the context of expensive biotechnology medicines, it supports the argument that government healthcare policies must take account of the practical availability of essential treatment.

It does not, however, establish an unconditional right to publicly funded access to every newly developed biological medicine.

6.7 State of Punjab v. Mohinder Singh Chawla (1997) 2 SCC 83

Background:

The case concerned medical treatment and reimbursement obligations of the State towards its employees.

Judgment:

The Supreme Court recognised that the right to health is integral to the right to life under Article 21.

Relevance:

The case is relevant to reimbursement policies for expensive medicines and the legal responsibility of public authorities to provide appropriate medical facilities.

It supports a rights-based approach to healthcare financing, although reimbursement remains subject to the applicable legal and administrative framework.

6.8 R (Rogers) v. Swindon PCT — Broader significance for public-law review

The Herceptin litigation is especially valuable when examining the relationship between individual treatment requirements and collective healthcare expenditure.

It establishes that financial resource allocation must be accompanied by rational criteria and cannot be administered through arbitrary patient classifications.

For Indian regulatory scholarship, the judgment provides a comparative model for reviewing government decisions concerning access to high-cost biological medicines.

7. International Regulatory Framework

7.1 United Kingdom: NICE

The National Institute for Health and Care Excellence (NICE) evaluates medicines and healthcare technologies for use within the NHS.

Its assessment may include:

Clinical effectiveness.

Cost-effectiveness.

Incremental cost per QALY.

Uncertainty in clinical evidence.

Patient perspectives.

Severity of disease.

Resource implications.

NICE recommendations have substantial implications for NHS funding and access to innovative medicines.

The Herceptin litigation in Rogers v. Swindon PCT illustrates the importance of lawful and consistent implementation of treatment-funding policies.

7.2 European Union: Regulation (EU) 2021/2282

The European Union adopted Regulation (EU) 2021/2282 on Health Technology Assessment.

It has applied since 12 January 2025.

The framework introduces cooperation between Member States concerning:

Joint clinical assessments.

Joint scientific consultations.

Identification of emerging health technologies.

Cooperation in clinical evidence evaluation.

Reduction of duplicated assessment procedures.

The framework is particularly relevant to innovative medicines, including advanced biotechnology therapies.

An important qualification is that EU-level joint clinical assessment does not itself impose a single EU-wide medicine price or reimbursement decision. National authorities retain important responsibilities concerning economic assessment, pricing and reimbursement.

Public Health+2

7.3 United States: Medicare and Medicaid

In the United States, cost-effectiveness regulation operates through a more fragmented framework.

Important institutions include:

Food and Drug Administration (FDA).

Centers for Medicare & Medicaid Services (CMS).

Medicaid programmes.

Institute for Clinical and Economic Review (ICER), an independent research organisation.

FDA approval primarily addresses safety and efficacy, while coverage and reimbursement involve separate legal and administrative processes.

Medicare's statutory framework also restricts the use of certain cost-effectiveness measures in specified coverage determinations. Therefore, economic value assessment should not be confused with an unrestricted authority to deny treatment solely because of a cost-per-QALY calculation.

8. Special Problems in Regulating Biotech Drugs

8.1 Extremely High Prices of Gene Therapies

Gene therapies may involve one-time treatment costs running into millions of rupees or substantially more.

Traditional cost-effectiveness models may underestimate or overestimate their value because long-term clinical outcomes are uncertain.

Regulators must examine:

Durability of therapeutic effects.

Possibility of disease recurrence.

Long-term adverse effects.

Lifetime healthcare savings.

Manufacturing costs.

Patient eligibility.

8.2 Rare Diseases and Orphan Drugs

Orphan drugs are developed for conditions affecting relatively small populations.

Their prices may be exceptionally high because manufacturers have fewer potential patients over whom to distribute research and development expenditure.

A purely mathematical cost-effectiveness threshold may exclude treatments for rare diseases.

A balanced framework should therefore consider disease severity, unmet medical need, treatment alternatives and the social value of improving the lives of patients with rare diseases.

8.3 Uncertainty in Clinical Evidence

Some biotech drugs receive approval based on surrogate endpoints, limited trial populations or accelerated regulatory pathways.

Long-term survival benefits may remain uncertain.

Regulators should therefore require:

Post-marketing surveillance.

Real-world evidence.

Long-term clinical follow-up.

Periodic reassessment.

Transparent reporting of adverse events.

8.4 Biosimilar Substitution

Biosimilars can improve affordability, but substitution policies must consider the nature of the biological product.

Regulatory authorities must distinguish scientific biosimilarity from automatic pharmacy-level substitution.

Appropriate rules should address physician oversight, patient information, traceability and pharmacovigilance.

8.5 Confidential Pricing Agreements

Manufacturers may negotiate confidential discounts with government purchasers.

Although these agreements may produce lower prices, excessive confidentiality can undermine public accountability.

Regulators should maintain sufficient transparency concerning procurement criteria, public expenditure and the reasons for reimbursement decisions.

9. Constitutional and Human Rights Dimensions

Cost-effectiveness regulation must operate within the broader constitutional framework of healthcare rights.

Article 14: Equality Before Law

Government healthcare funding decisions must not discriminate arbitrarily between similarly situated patients.

A patient should not be excluded from access to a biotech medicine through irrational or unsupported eligibility criteria.

Article 21: Right to Life

The right to life includes important dimensions of health and medical care.

Government policies affecting access to life-saving medicines must therefore be evaluated against constitutional principles.

Article 47: Public Health

Article 47 directs the State to regard improvement of public health as among its primary duties.

It supports policies aimed at improving access to essential medicines and strengthening public healthcare infrastructure.

International Human Rights Law

Article 12 of the International Covenant on Economic, Social and Cultural Rights recognises the right to the highest attainable standard of physical and mental health.

General Comment No. 14 of the UN Committee on Economic, Social and Cultural Rights discusses accessibility, availability, acceptability and quality of healthcare.

These principles provide a wider normative basis for regulating the affordability and distribution of innovative biological medicines.

10. Legal Challenges and Regulatory Accountability

A cost-effectiveness decision concerning a biotech drug may be challenged on several grounds.

Judicial review should examine the legality, rationality and procedural fairness of the decision without automatically substituting judicial preferences for expert medical and economic assessments.

11. Proposed Model for Effective Cost-Effectiveness Regulation in India

India requires a balanced regulatory model that integrates economic evaluation, public-health priorities and biotechnology innovation.

The following reforms would strengthen the existing framework.

11.1 Mandatory economic evaluation for publicly funded high-cost therapies

Expensive gene therapies, monoclonal antibodies and advanced biological medicines should undergo structured HTA before inclusion in major publicly funded treatment programmes.

11.2 Transparent cost-effectiveness methodology

HTA assessments should disclose:

Clinical evidence and comparator selection.

ICER calculations.

QALY assumptions.

Budget impact.

Uncertainty analysis.

Patient and public-health considerations.

11.3 Special consideration for rare diseases

A separate assessment pathway should recognise the distinctive circumstances of orphan drugs and treatments for life-threatening conditions.

11.4 Performance-based reimbursement

Government purchasers should consider outcome-linked payment agreements for expensive therapies where long-term effectiveness is uncertain.

11.5 Strengthening biosimilar competition

India should encourage competitive biosimilar markets through effective regulatory review, appropriate procurement policies and protection against anti-competitive practices.

11.6 Independent regulatory review

Manufacturers should have access to a fair review mechanism when they dispute the methodology, evidence or procedural fairness of an HTA decision.

11.7 Protection against financial toxicity

Cost-effectiveness decisions should consider the financial burden on patients, particularly those who would otherwise incur substantial out-of-pocket expenditure.

12. Critical Analysis

Cost-effectiveness regulation presents a fundamental conflict between economic efficiency and individual healthcare rights.

A medicine may be clinically effective but economically expensive. Conversely, a relatively inexpensive medicine may produce only marginal improvements in patient outcomes.

The central difficulty is determining how much society should spend to achieve additional health benefits.

Three competing regulatory philosophies emerge.

First: Market-oriented regulation

This approach gives considerable importance to patent protection, market competition and pharmaceutical innovation.

Its weakness is that monopoly pricing may make essential treatments inaccessible.

Second: Public-health-oriented regulation

This approach prioritises affordability, universal access and equitable distribution of healthcare resources.

Its weakness is that excessive price restrictions may discourage investment in biotechnology research and development.

Third: Evidence-based economic regulation

This approach combines clinical evaluation, cost-effectiveness analysis, budget impact assessment and public-health priorities.

It offers a more balanced regulatory model, although its success depends on transparent methodology, reliable evidence and accountable decision-making.

For India, the third approach is particularly important because the healthcare system must simultaneously address infectious diseases, cancer, rare genetic disorders and the growing demand for advanced biological treatments.

13. Conclusion

Cost-Effectiveness Regulation of Biotech Drugs represents an important development in modern pharmaceutical and healthcare law.

It recognises that scientific innovation alone cannot determine the accessibility of advanced biological medicines. Their economic value, therapeutic benefits, affordability and consequences for public healthcare expenditure must also be considered.

In India, the interaction between the Drugs and Cosmetics Act, 1940, the Essential Commodities Act, 1955, DPCO 2013, the Patents Act, 1970, the Competition Act, 2002 and the institutional framework of HTAIn creates a foundation for regulating the economic and legal dimensions of biotechnology medicines.

Judicial decisions such as Novartis AG v. Union of India, Bayer Corporation v. Union of India, Union of India v. Cynamide India Ltd. and Paschim Banga Khet Mazdoor Samity v. State of West Bengal provide important principles concerning pharmaceutical patents, public affordability, governmental price regulation and constitutional healthcare obligations.

Ultimately, the objective should not be to make every expensive biotech drug inexpensive irrespective of its therapeutic value, nor to allow every innovative medicine to command an unrestricted price. The objective should be to create a transparent, scientifically defensible and constitutionally compatible regulatory framework that rewards genuine innovation while protecting patients and ensuring sustainable healthcare expenditure.

14. Important Case Law Reference Table

Citation clarification: The Bayer compulsory-licensing proceedings involved multiple judicial stages. The Bombay High Court decision of 15 July 2014 and the Delhi High Court proceedings should be distinguished; they should not be treated as a single Supreme Court judgment bearing the citation previously stated.

15. Important Legal and Regulatory Sources

HTAIn Manual – Government of India.

HTAIn – Background, mandate and objectives.

Drugs (Prices Control) Order, 2013 – NPPA.

Novartis AG v. Union of India – Supreme Court judgment.

Bayer Corporation v. Union of India – Delhi High Court.

Rogers v. Swindon PCT – Court of Appeal.

EU Health Technology Assessment Regulation – Implementation.

Overall academic proposition: Cost-effectiveness regulation of biotech drugs is best understood as the legal governance of the relationship between therapeutic innovation, economic efficiency, intellectual-property protection and the constitutional right to accessible healthcare.